Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2

View ORCID ProfileKatherine Laiton-Donato, View ORCID ProfileCarlos Franco-Muñoz, View ORCID ProfileDiego A. Álvarez-Díaz, Hector Alejandro Ruiz-Moreno, View ORCID ProfileJose A. Usme-Ciro, View ORCID ProfileDiego Andrés Prada, View ORCID ProfileJhonnatan Reales-González, View ORCID ProfileSheryll Corchuelo, View ORCID ProfileMaría T. Herrera-Sepúlveda, View ORCID ProfileJulian Naizaque, Gerardo Santamaría, View ORCID ProfileJorge Rivera, View ORCID ProfilePaola Rojas, View ORCID ProfileJuan Hernández Ortiz, View ORCID ProfileAndrés Cardona, View ORCID ProfileDiana Malo, View ORCID ProfileFranklin Prieto-Alvarado, Fernando Ruiz Gómez, View ORCID ProfileMagdalena Wiesner, View ORCID ProfileMartha Lucia Ospina Martínez, View ORCID ProfileMarcela Mercado-Reyes
doi: https://doi.org/10.1101/2021.05.08.21256619
Katherine Laiton-Donato
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katherine Laiton-Donato
  • For correspondence: kdlaitond@unal.edu.co
Carlos Franco-Muñoz
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carlos Franco-Muñoz
Diego A. Álvarez-Díaz
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Diego A. Álvarez-Díaz
Hector Alejandro Ruiz-Moreno
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose A. Usme-Ciro
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
bCentro de Investigación en Salud para el Trópico - CIST, Facultad de Medicina, Universidad Cooperativa de Colombia, Santa Marta, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jose A. Usme-Ciro
Diego Andrés Prada
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Diego Andrés Prada
Jhonnatan Reales-González
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jhonnatan Reales-González
Sheryll Corchuelo
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sheryll Corchuelo
María T. Herrera-Sepúlveda
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for María T. Herrera-Sepúlveda
Julian Naizaque
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Julian Naizaque
Gerardo Santamaría
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Rivera
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jorge Rivera
Paola Rojas
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paola Rojas
Juan Hernández Ortiz
cLaboratorio Genómico One Health. Medellín, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Juan Hernández Ortiz
Andrés Cardona
cLaboratorio Genómico One Health. Medellín, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrés Cardona
Diana Malo
dDirección de Vigilancia en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Diana Malo
Franklin Prieto-Alvarado
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Franklin Prieto-Alvarado
Fernando Ruiz Gómez
eMinisterio de Salud y Protección Social de Colombia. Bogotá Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdalena Wiesner
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Magdalena Wiesner
Martha Lucia Ospina Martínez
fDirección General, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martha Lucia Ospina Martínez
Marcela Mercado-Reyes
aGroup Genomics of Emerging Microorganisms. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marcela Mercado-Reyes
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

SARS-CoV-2 genetic diversity has the potential to impact the virus transmissibility and the escape from natural infection- or vaccine-elicited neutralizing antibodies. Here, we report the emergence of the B.1.621 lineage, considered a variant of interest (VOI) with the accumulation of several mutations affecting the Spike protein, including the amino acid changes I95I, Y144T, Y145S and the insertion 146N in the N-terminal domain, R346K, E484K and N501Y in the Receptor Binding Domain and P681H in the S1/S2 cleavage site of the Spike protein. The rapid increase in frequency and fixation in a relatively short time in some cities that were near the theoretical herd immunity suggests an epidemiologic impact. Further studies will be required to assess the biological and epidemiologic roles of the substitution pattern found in the B.1.621 lineage.

Introduction

In September 2020, SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI) started to be reported, with more distinctive mutations than expected from the characteristic clock-like molecular evolution of this virus evidenced during the first year pandemic (1,2). Despite mutations spanning the whole genome, an interesting feature of these emerging variants has been the presence of several amino acid substitutions falling in the Spike protein, the viral protein responsible for receptor binding and membrane fusion and also the main target for neutralizing antibodies (3). Monitoring the emergence of new variants of SARS-CoV-2 is a priority worldwide, as the presence of certain non-synonymous substitutions and INDELs could be related to biological properties, such as altering the ligand-receptor affinity, the efficiency of neutralization by naturally acquired polyclonal immunity or post-vaccination antibodies and transmission capacity (4–6).

In Colombia, the National Genomic Characterization Program led by the Instituto Nacional de Salud has carried out real-time monitoring of the SARS-CoV-2 lineages since the beginning of the pandemic (7,8). Until December 2020, over thirty lineages were circulating inside the country without evidence of VOC and VOI importation. However, a lineage turnover accompanied the third epidemic peak during March and April 2021, involving the emergence of B.1 lineage descendants with high mutation accumulation (B.1.621 and the provisionally assigned B.1+L249S+E484K) (9), as well as the introduction of the B.1.1.7, P.1 and VOI in some cities.

In this study, we reported the emergence and spread of the novel B.1.621 lineage of SARS-CoV-2, a new VOI with the insertion 146N and several amino acid substitutions in the Spike protein (Y144T, Y145S, R346K, E484K, N501Y and P681H).

Methods

Samples were selected from routine surveillance in all departments based on representativeness and virologic criteria (10). Respiratory samples were used for automated RNA extraction with magnetic beads and the RNA extracts were processed by using the amplicon sequencing protocol v3 (https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye). The assembly of raw NGS data was performed by following the pipeline described for Oxford Nanopore Technologies (ONT) platform (https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html).

Lineage assignment started by filing a new issue in the pango-designation repository (https://github.com/cov-lineages/pango-designation/issues/57) followed by designation as B.1.621 lineage by the Pangolin curation team and PangoLEARN model training for subsequent automatic lineage assignment.

Maximum likelihood tree reconstruction was performed with the GTR+F+I+G4 nucleotide substitution model using IQTREE. Branch support was estimated with an SH-like approximate likelihood ratio test (SH-aLRT). Recombination detection was performed using RDP4 software with RDP, GENECONV, Bottscan, Maxchi, Chimaera, SiSscan, and 3Seq tests (P-value < 0.05). Dataset 1 included Colombian SARS-CoV-2 sequences representative of the different lineages and dataset 2 included sequences previously reported as VOC or VOI. Adaptive evolution analysis at the codon level was estimated by Hyphy using stochastic evolutionary models. The detection of individual sites was performed with methods such as MEME (Mixed Effects Model of Evolution), and FEL (Fixed Effects Likelihood) (P-value <0.3).

Results

Lineage B.1.621 has become predominant in some departments of Colombia

The routine genomic surveillance of SARS-CoV-2 in Colombia was reinforced in January 2021 for a higher sensitivity monitoring of the potential importation of VOC. By May 7, 2021, a total of 908 sequences from Colombia were available in the GISAID database. Lineage B.1 is the best-represented lineage (with 229 records) due to its higher frequency from the beginning of the pandemic. The recently designated B.1.621 lineage has been increasingly detected from January 11, 2021 (collection date of the first genome belonging to the lineage) to date (77 records), occupying the fifth place in frequency(Figure 1A), rapidly becoming fixed in some departments located in the North of the country or co-circulating with others lineages in Bogotá D.C. (Figure 1B). The genetic background of the B.1.621 lineage includes some convergent amino acid changes previously found in several VOI and VOC.

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Percent in time of variant B.1.621 in Spain. USA and Colombia.1a) Gisaid registries of variant B.1.621 in 2021. Since January the continuous record has been maintained in Colombia. 1b) Lineage percentage and number of cases of COVID-19 in five departments with circulation of B.1.621 variant and the capital city. B.1.1.7 and P.1 VOC lineages are shown, others lineages circulating are represented as “others”.

The original assignment through the Pangolin algorithm for this monophyletic group was the B.1 lineage. However, a large number of distinctive synonymous and non-synonymous substitutions, including the following amino acid changes I95I, Y144T, Y145S in the N-terminal domain; R346K, E484K and N501Y in the Receptor Binding Domain and P681H in the S1/S2 cleavage site (Table 1) and the insertion 146N (supplementary table 1) in the Spike protein.

View this table:
  • View inline
  • View popup
Table1:

Nucleotide and amino acid substitution pattern of B.1.621

Lineage B.1.621 emerged from the parental B.1 lineage circulating in Colombia

The close phylogenetic relationship of the SARS-CoV-2 sequences belonging to the B.1.621 lineage with other sequences from representative lineages circulating worldwide and those circulating in Colombia suggested a recent origin from the parental lineage B.1 (Figure 2a), which was corroborated through the lineage designation (https://github.com/cov-lineages/pango-designation/issues/57) (supplementary table 2). B.1.621 lineage has recently spread to fourteen departments, with a major representation in the Caribbean region of Colombia (Figure 2b) (https://microreact.org/project/5CAiK3qCMaEgE4vYkKVpZW/b7113efc). No recombination events were found throughout the whole genome (data not shown). At least 9 codons in the Spike protein displayed a signal suggestive of positive selection (supplementary table 3).

Figure 2.
  • Download figure
  • Open in new tab
Figure 2.

Phylogeny and distribution of SARS-CoV-2 b.1.621 variant in Colombia 2a) Phylogenetic tree of the new lineage of SARS-CoV-2 emerging from B.1.621 lineage. The tree was reconstructed by maximum likelihood with the estimated GTR+F+I+G4 nucleotide substitution model for the dataset of 434 genomes. The interactive tree can be accessed in the following link: https://microreact.org/project/5CAiK3qCMaEgE4vYkKVpZW/b7113efc 2b) Map of distribution of lineages across the country

Discussion

All genomes belonging to the B.1.621 lineage available until the end of April 2021 were included in this study, with the earliest collection date on January 11th. 2021, corresponding to a sample collected in the department of Magdalena, Colombia (EPI_ISL_1220045). While a very high and unexplained genetic distance is found between every B.1.621 sequence and all closely related sequences of the parental B.1 lineage, the whole branching pattern and intra-lineage distance suggest low diversification that can be explained by its recent origin. The spread in the country early during the third peak of the pandemic could be explained by a combination of factors, including social exhaustion as well as the genetic background of the emerging lineage, leading to changes in transmission.

In Colombia, the current strategy for SARS-CoV-2 genomic surveillance includes sampling in principal and border cities, in special groups of interest, in patients with distinctive clinical features and severity, and finally in community transmission with an unusual increase in cases. The high frequency of the emerging B.1.621 lineage also could be related to the strengthening of the SARS-COV-2 genomic surveillance during the third peak of the pandemic in Colombia, nevertheless, it is expected to characterize an approximate 1% of the cases and determine the adjusted frequency of the lineage in the country and to evaluate the possible predominance and the replacement of other lineages in the country. For this, intensified genomic characterization will be carried out with a multi-stage sample design throughout the national territory.

During the first quarter of 2021, several convergent substitutions have been evidenced in the different lineage of SARS-CoV-2 explained by a high rate of the naive population that has explored wide options of genetic variability, the other scenario is explained by the selection pressure by monoclonal antibody therapies (11,12) and vaccination (13,14). The distinctive substitutions observed in the spike protein are common, despite the characteristics attributed to some substitutions, for instance, the presence of E484K has been associated with lower neutralizing activity from convalescent plasma(12). The 69/70 deletion spike together with the E484K and N501Y substitutions decrease the ability to neutralize antibodies (15). The insertion 145N in the spike protein is the first evidence in SARS-CoV-2, the implications at the level of infection, transmission and pathogenesis are still unknown.

The B.1.621 lineage includes substitutions targets in RT-PCR screening of VOC lineages (16), this should be considered in the analysis of RT-PCR results considering the occurrence of these mutations in other lineages could lead to overestimating the number of cases caused for VOC lineages.

The B.1.621 lineage was identified in Colombia, USA and Spain. The study was limited to genomic and evolutionary characterization, the public health implications must be to assess through the biological and epidemiologic roles.

Data Availability

All data is available in GISAID database, the phylogenetic analysis is available in a microreact site https://microreact.org/project/5CAiK3qCMaEgE4vYkKVpZW/b7113efc.

https://microreact.org/project/5CAiK3qCMaEgE4vYkKVpZW/b7113efc.

https://www.GISAID.org

Disclosure statement

No conflict of interest was reported by the authors.

Funding

This work was funded by the Project CEMIN-4-2020 Instituto Nacional de Salud. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data deposition

View this table:
  • View inline
  • View popup

Acknowledgements

The authors thank the National Laboratory Network for routine virologic surveillance of SARS-CoV-2 in Colombia. We also thank all researchers who deposited genomes in GISAID’s EpiCoV Database contributing to genomic diversity and phylogenetic relationship of SARS-CoV-2. We thank Rotary International and Charlie Rut Castro for equipment’s donation. Finally, we thank red RENATA and Universidad Industrial de Santander for the workstation bioinformatic support.

References

  1. 1.↵
    ECDC. SARS-CoV-2 variants of concern as of 4 May 2021 [Internet]. [cited 2021 May 4]. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern
  2. 2.↵
    Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications. N Engl J Med [Internet]. 2021 Mar 24 [cited 2021 Apr 30];NEJMc2100362. Available from: http://www.nejm.org/doi/10.1056/NEJMc2100362
  3. 3.↵
    Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe [Internet]. 2021 Mar 10 [cited 2021 Apr 30];29(3):463-476.e6. Available from: https://pubmed.ncbi.nlm.nih.gov/33592168/
    OpenUrl
  4. 4.↵
    Rees-Spear C, Muir L, Sa G, Heaney J, Aldon Y, Jl S, et al. The impact of Spike mutations on SARS-CoV-2 neutralization 1. bioRxiv [Internet]. 2021 Jan 19 [cited 2021 Mar 2];4:2021.01.15.426849. Available from: https://doi.org/10.1101/2021.01.15.426849
  5. 5.
    Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies [Internet]. Vol. 20, Nature Reviews Immunology. Nature Research; 2020 [cited 2021 Apr 30]. p. 615–32. Available from: https://doi.org/10.1038/
    OpenUrl
  6. 6.↵
    Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (80-) [Internet]. 2021 Apr 9 [cited 2021 Apr 30];372(6538):eabg3055. Available from: https://science.sciencemag.org/content/372/6538/eabg3055
    OpenUrl
  7. 7.↵
    Laiton-Donato K, Villabona-Arenas CJ, Usme-Ciro JA, Franco-Muñoz C, Álvarez-Díaz DA, Villabona-Arenas LS, et al. Genomic epidemiology of severe acute respiratory syndrome coronavirus 2, Colombia. Emerg Infect Dis [Internet]. 2020 Dec 1 [cited 2021 Apr 30];26(12):2854–62. Available from: www.biorxiv.org/content/10.1101/2020.05.21.10932
    OpenUrl
  8. 8.↵
    Noticias coronavirus-genoma [Internet]. [cited 2021 Apr 30]. Available from: https://www.ins.gov.co/Noticias/Paginas/coronavirus-genoma.aspx
  9. 9.↵
    Laiton-Donato K, Usme-Ciro JA, Franco-Muñoz C, Álvarez-Díaz DA, Ruiz-Moreno HA, Reales-González J, et al. Novel highly divergent SARS-CoV-2 lineage with the Spike substitutions L249S and E484K. medRxiv pre-print [Internet]. 2021 Mar 15 [cited 2021 May 7];2021.03.12.21253000. Available from: https://doi.org/10.1101/2021.03.12.21253000
  10. 10.↵
    PAHO. Guidance for SARS-CoV-2 samples selection for genomic characterization and surveillance - PAHO/WHO | Pan American Health Organization [Internet]. [cited 2021 May 7]. Available from: https://www.paho.org/en/documents/guidance-sars-cov-2-samples-selection-genomic-characterization-and-surveillance
  11. 11.↵
    Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med [Internet]. 2021 Apr 1 [cited 2021 Apr 30];27(4):622–5. Available from: https://doi.org/10.1038/s41591-021-01285-x
    OpenUrl
  12. 12.↵
    Liu Z, VanBlargan LA, Bloyet L-M, Rothlauf PW, Chen RE, Stumpf S, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe [Internet]. 2021 Mar 10 [cited 2021 May 1];29(3):477-488.e4. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1931312821000445
    OpenUrl
  13. 13.↵
    Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature [Internet]. 2021 Feb 10 [cited 2021 Apr 30];592(7855):616–22. Available from: https://www.nature.com/articles/s41586-021-03324-6
    OpenUrl
  14. 14.↵
    Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell [Internet]. 2021 Apr 29 [cited 2021 May 1];184(9):2372-2383.e9. Available from: https://doi.org/10.1016/j.cell.2021.03.013
    OpenUrl
  15. 15.↵
    Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med [Internet]. 2021 Apr 1 [cited 2021 May 1];27(4):620–1. Available from: https://doi.org/10.1038/s41591-021-01270-4
    OpenUrl
  16. 16.↵
    Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, et al. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69–V70, France, August to December 2020. Eurosurveillance [Internet]. 2021 Jan 21 [cited 2021 May 4];26(3):2100008. Available from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.3.2100008
    OpenUrl
Back to top
PreviousNext
Posted May 10, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2
Katherine Laiton-Donato, Carlos Franco-Muñoz, Diego A. Álvarez-Díaz, Hector Alejandro Ruiz-Moreno, Jose A. Usme-Ciro, Diego Andrés Prada, Jhonnatan Reales-González, Sheryll Corchuelo, María T. Herrera-Sepúlveda, Julian Naizaque, Gerardo Santamaría, Jorge Rivera, Paola Rojas, Juan Hernández Ortiz, Andrés Cardona, Diana Malo, Franklin Prieto-Alvarado, Fernando Ruiz Gómez, Magdalena Wiesner, Martha Lucia Ospina Martínez, Marcela Mercado-Reyes
medRxiv 2021.05.08.21256619; doi: https://doi.org/10.1101/2021.05.08.21256619
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2
Katherine Laiton-Donato, Carlos Franco-Muñoz, Diego A. Álvarez-Díaz, Hector Alejandro Ruiz-Moreno, Jose A. Usme-Ciro, Diego Andrés Prada, Jhonnatan Reales-González, Sheryll Corchuelo, María T. Herrera-Sepúlveda, Julian Naizaque, Gerardo Santamaría, Jorge Rivera, Paola Rojas, Juan Hernández Ortiz, Andrés Cardona, Diana Malo, Franklin Prieto-Alvarado, Fernando Ruiz Gómez, Magdalena Wiesner, Martha Lucia Ospina Martínez, Marcela Mercado-Reyes
medRxiv 2021.05.08.21256619; doi: https://doi.org/10.1101/2021.05.08.21256619

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1095)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9766)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1557)
  • Health Policy (734)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11639)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1175)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4654)
  • Radiology and Imaging (776)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)